IL-31 was able to reduce the mortality rate of lipopolysaccharide (LPS)-induced sepsis, by a reduction in the inflammatory cytokines and inhibition of IL-1β production in LPS-induced sepsis. This evidence concerns the gene IL1B and Sepsis.